Pharmacological and pharmacokinetic aspects of functional gastrointestinal disorders

被引:50
作者
Camilleri, Michael
Bueno, Lionel
de Ponti, Fabrizio
Fioramonti, Jean
Lydiard, R. Bruce
Tack, Jan
机构
[1] Mayo Clin, Coll Med, Rochester, MN 55905 USA
[2] INSERM, F-31073 Toulouse, France
[3] Univ Bologna, I-40126 Bologna, Italy
[4] Univ S Carolina, Charleston, SC USA
[5] Catholic Univ Louvain, B-3000 Louvain, Belgium
关键词
D O I
10.1053/j.gastro.2005.08.062
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Medications are commonly used for the treatment of patients with functional gastrointestinal disorders. The general goal of this report is to review the pharmacokinetics and pharmacology of medications used in functional gastrointestinal disorders. Methods included literature review, consensus evaluation of the evidence for each topic assigned originally to 1 or 2 authors, and broader review at a harmonization session as part of the Rome III process. This report reviews the animal models that have been validated for the study of effects of pharmacologic agents on sensation and motility; the preclinical pharmacology, pharmacokinetics, and toxicology usually required for introduction of novel therapeutic agents; the biomarkers validated for studies of sensation and motility end points with experimental medications in humans; the pharmacogenomics applied to these medications and disorders; and the pharmacology of agents that are applied or have potential for treatment of functional gastrointestinal disorders, including psychopharmacologic agents. Clinician and basic investigators involved in the treatment or investigation of functional gastrointestinal disorders or disease models need to have a comprehensive understanding of a vast range of medications. It is anticipated that the interaction between investigators of basic science, basic and applied pharmacology, and clinical trials will lead to better treatment of these disorders.
引用
收藏
页码:1421 / 1434
页数:14
相关论文
共 121 条
[81]   Effects of nematode infection on sensitivity to intestinal distension: Role of tachykinin NK2 receptors [J].
McLean, PG ;
Picard, C ;
GarciaVillar, R ;
More, J ;
Fioramonti, J ;
Bueno, L .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 337 (2-3) :279-282
[82]   From magic bullets to designed multiple ligands [J].
Morphy, R ;
Kay, C ;
Rankovic, Z .
DRUG DISCOVERY TODAY, 2004, 9 (15) :641-651
[83]   EXPERIMENTAL COLITIS ALTERS VISCEROMOTOR RESPONSE TO COLORECTAL DISTENSION IN AWAKE RATS [J].
MORTEAU, O ;
HACHET, T ;
CAUSSETTE, M ;
BUENO, L .
DIGESTIVE DISEASES AND SCIENCES, 1994, 39 (06) :1239-1248
[84]   Alosetron: a case study in regulatory capture, or a victory for patients' rights? [J].
Moynihan, R .
BRITISH MEDICAL JOURNAL, 2002, 325 (7364) :592-595
[85]   Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation [J].
Müller-Lissner, SA ;
Fumagalli, I ;
Bardhan, KD ;
Pace, F ;
Pecher, E ;
Nault, B ;
Rüegg, P .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (10) :1655-1666
[86]   COLORECTAL DISTENSION AS A NOXIOUS VISCERAL STIMULUS - PHYSIOLOGIC AND PHARMACOLOGIC CHARACTERIZATION OF PSEUDAFFECTIVE REFLEXES IN THE RAT [J].
NESS, TJ ;
GEBHART, GF .
BRAIN RESEARCH, 1988, 450 (1-2) :153-169
[87]   A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation [J].
Novick, J ;
Miner, P ;
Krause, R ;
Glebas, K ;
Bliesath, H ;
Ligozio, G ;
Rüegg, P ;
Lefkowitz, M .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (11) :1877-1888
[88]   Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs [J].
Nugent, SG ;
Kumar, D ;
Rampton, DS ;
Evans, DF .
GUT, 2001, 48 (04) :571-577
[89]  
OMAHONY L, IN PRESS GASTROENTER
[90]   Models of gastric hyperalgesia in the rat [J].
Ozaki, N ;
Bielefeldt, K ;
Sengupta, JN ;
Gebhart, GF .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2002, 283 (03) :G666-G676